Recent CARM News
- Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna • PR Newswire (US) • 06/27/2024 08:30:00 PM
- Carisma Therapeutics Granted FDA Fast Track Designation for CT-0525 for the Treatment of HER2-overexpressing Solid Tumors • PR Newswire (US) • 06/25/2024 11:30:00 AM
- Carisma Therapeutics to Participate in the Stifel 2024 Cell Therapy Forum • PR Newswire (US) • 06/25/2024 11:30:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/18/2024 11:06:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:32:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/14/2024 08:30:21 PM
- Carisma Therapeutics Announces Adjournment of Annual Meeting of Stockholders • PR Newswire (US) • 06/13/2024 08:30:00 PM
- Information Concerning the Total Number of Voting Rights and Share • Business Wire • 06/05/2024 03:45:00 PM
- Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers • Business Wire • 06/05/2024 03:45:00 PM
- Carisma Therapeutics to Participate in the Jefferies Global Healthcare Conference • PR Newswire (US) • 05/30/2024 11:30:00 AM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/28/2024 11:39:56 PM
- Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte • PR Newswire (US) • 05/16/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 11:52:53 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:41:02 AM
- Carisma Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights • PR Newswire (US) • 05/09/2024 11:30:00 AM
- Carmila: Réduction des moyens du contrat de liquidité • Business Wire • 05/08/2024 03:45:00 PM
- Carmila: Withdrawal of funds for the liquidity contract • Business Wire • 05/08/2024 03:45:00 PM
- Carisma Therapeutics Presents Preclinical Proof of Concept Data Demonstrating the Anti-Fibrotic Potential of Engineered Macrophages at ASGCT 2024 • PR Newswire (US) • 05/08/2024 11:30:00 AM
- Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L.233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des marchés financiers • Business Wire • 05/07/2024 03:45:00 PM
- Information Concerning the Total Number of Voting Rights and Share • Business Wire • 05/07/2024 03:45:00 PM
- Carisma Therapeutics to Participate in The Citizens JMP Life Sciences Conference • PR Newswire (US) • 05/06/2024 11:30:00 AM
- Carisma Therapeutics Appoints Dr. Eugene P. Kennedy as Chief Medical Officer • PR Newswire (US) • 05/02/2024 11:30:00 AM
- Carisma Therapeutics Announces Upcoming Presentation at the American Society of Clinical Oncology (ASCO) 2024 Annual Meeting • PR Newswire (US) • 04/24/2024 09:05:00 PM
- Carmila : Lancement d’un programme de rachat d’actions pour 10 millions d’euros • Business Wire • 04/24/2024 04:43:00 PM
- Carmila: Launch of a Share Buyback Program for €10 Million • Business Wire • 04/24/2024 04:43:00 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM